SS 38 - GU 2: Optimizing the Therapeutic Ratio in Prostate Cancer

Moderator(s)

• 

  David Miyamoto, MD, PhD

  Massachusetts General Hospital
  Boston, MA, United States
• 

  Catherine Spina, MD, PhD

  Columbia University Irving Medical Center
  New York, NY

Presentations:

• 4:00 PM – 4:10 PM ET

  Magnetic Resonance Imaging-Guided vs. Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial
  

  Presenter: Amar Kishan, MD – UCLA Radiation Oncology
• 4:10 PM – 4:20 PM ET

  Volumetric Changes and Acute Toxicity with 68Ga Prostate-Specific Membrane Antigen vs 18F-Fluciclovine PET/CT Guided Post-Prostatectomy Radiation: Final Analysis of a Randomized Trial
  

  Presenter: Vishal Dhere, MD – Emory University
• 4:20 PM – 4:30 PM ET

  Dose Escalated Pelvic Lymph Node Intensity Modulated Radiation Therapy (IMRT) with a Simultaneous Hypofractionated Boost to the Prostate for NCCN Very-High Risk Adenocarcinoma of the Prostate, a Prosp
  

  Presenter: William Hall, MD – Medical College of Wisconsin (MCW)
• 4:30 PM – 4:40 PM ET

  Initial Results of a Multi-Institutional Phase 1/2 Trial of Focal Dose-Escalated Salvage High Dose Rate Brachytherapy for Radiorecurrent Prostate Cancer (F-SHARP)
  

  Presenter: Abhishek Solanki, MD, MS – Loyola University Chicago Stritch School of Medicine
• 4:40 PM – 4:50 PM ET

  Focal MR-Guided HDR Brachytherapy Boost Combined with SBRT for Localized Prostate Cancer
  

  Presenter: Carlton Johnny, MD – Princess Margaret Cancer Center, University Health Network
• 4:50 PM – 5:00 PM ET

  Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for Unfavorable Intermediate and High-Risk Prostate Cancer; Early Results of PBS: A Phase I
  

  Presenter: Andre Gouveia, MD – McMaster University